Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6430235 | 0.86 | TRPV1 (0.70) | TRPV1 | |
| SCHEMBL13930769 | 0.85 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL4262793 | 0.85 | TRPV1 (0.82) | TRPV1CA12CA1CA2CA9 | |
| SCHEMBL3712104 | 0.84 | TRPV1 (0.80) | TRPV1CA12CA1CA2CA9 | |
| SCHEMBL6430919 | 0.82 | TRPV1 (0.77) | TRPV1CA12CA1CA2CA9 | |
| SCHEMBL6430862 | 0.82 | ALDH1A1 (0.62) | TRPV1 | |
| SCHEMBL4262868 | 0.80 | TRPV1 (0.77) | TRPV1CA12CA1CA2CA9 | |
| SCHEMBL13930770 | 0.79 | TRPV1 (0.70) | TRPV1 | |
| SCHEMBL4269392 | 0.78 | TRPV1 (0.73) | TRPV1CA12CA1CA2CA9 | |
| SCHEMBL12190505 | 0.77 | GAA (0.64) | TRPV1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176443-A1 | Capsaicin receptor ligands | NEUROGEN CORPORATION | 2004-09-09 | — | — | US | claimed |
| US-6723730-B2 | DIARYL PIPERAZINES AND RELATED COMPOUNDS USEFUL IN THE TREATMENT OF A CHRONIC AND ACUTE PAIN CONDITIONS, ITCH AND URINARY INCONTINENCE. | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| EP-1301484-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020132853-A1 | Capsaicin receptor ligands | NEUROGEN CORPORATION | 2002-09-19 | — | — | US | claimed |
| WO-2002008221-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-31 | — | — | WO | claimed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176443-A1 | Capsaicin receptor ligands | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885CA12 2322/4885CA1 2157/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | TRPV1 36/4885CA12 3808/4885CA1 1643/4885 |
| US-20020132853-A1 | Capsaicin receptor ligands | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885CA12 2322/4885CA1 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.